Share Price | GE Healthcare Technologies, Inc. Stock Analysis & Recommendation

Q: What does GE Healthcare Technologies, Inc. do?

Overview:GE Healthcare Technologies, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a large-cap company.Financial Snapshot:Most recent Net Sales: 4,777 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 588 Million (Quarterly Results - Mar 2025) Market cap: USD 32,573.94 Million Key Metrics:P/E: 14.00 Debt Equity: 0.70 Return on Equity: 25.79% Price to Book: 3.55 Contact Details:Registrar Address: Not available.

Q: Is GE Healthcare Technologies, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for GE Healthcare Technologies, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The daily moving averages are bearish, and the KST is bearish on a weekly basis. Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. In terms of returns, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.35% versus the S&P 500's 12.22%, and a one-year return of -16.41% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the bearish moving averages and mixed signals from MACD and Bollinger Bands.

Q: Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, which suggest that the stock is reasonably priced relative to its earnings growth potential.In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than Edwards Lifesciences Corp.'s P/E of 31.17 and Agilent Technologies, Inc.'s P/E of 27.42, indicating a more attractive valuation relative to these companies. Additionally, while GE Healthcare has underperformed against the S&P 500 with a year-to-date return of -9.66% compared to the index's 14.49%, this may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector.

Results Declared: GE Healthcare Technologies, Inc. has declared results on 29 Apr 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.06 M

Shareholding (Mar 2026)

FII

19.22%

Held by 447 FIIs

DII

34.92%

Held by 92 DIIs

Promoter

3.00%

How big is GE Healthcare Technologies, Inc.?

22-Jun-2025

As of Jun 18, GE Healthcare Technologies, Inc. has a market capitalization of $32.57 billion, with net sales of $19.80 billion and a net profit of $2.25 billion over the latest four quarters. The company reports shareholder's funds of $8.45 billion and total assets of $33.09 billion.

View full answer

What does GE Healthcare Technologies, Inc. do?

22-Jun-2025

GE Healthcare Technologies, Inc. is a large-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $4.777 billion and a net profit of $588 million. It has a market cap of approximately $32.57 billion, a P/E ratio of 14.00, and a return on equity of 25.79%.

View full answer

Is GE Healthcare Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, GE Healthcare Technologies, Inc. shows a mildly bearish trend with underperformance against the S&P 500, indicated by bearish moving averages and mixed MACD signals.

View full answer

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

18-Nov-2025

As of November 14, 2025, GE Healthcare Technologies, Inc. is considered fairly valued with a P/E ratio of 14, making it more attractive compared to peers like Edwards Lifesciences and Agilent Technologies, despite a year-to-date return of -9.66% compared to the S&P 500's 14.49%.

View full answer

Compare GE Healthcare Technologies, Inc. with Similar Stocks

Agilent Technologies, Inc.IDEXX Laboratories, Inc.DexCom, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 18.55%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.11 times

Flat results in Dec 25

With ROCE of 18.08%, it has a attractive valuation with a 2.41 Enterprise value to Capital Employed

High Institutional Holdings at 95.22%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 32,891 Million (Mid Cap)

P/E

15.00

Industry P/E

Dividend Yield

0.10%

Debt Equity

0.54

Return on Equity

20.79%

Price to Book

3.17

Revenue and Profits:

Net Sales:

5,131 Million

(Quarterly Results - Mar 2026)

Net Profit:

411 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.84%

6 Months

-19.27%

1 Year

-12.01%

2 Years

-23.19%

3 Years

-22.72%

4 Years

0.0%

5 Years

0.0%

GE Healthcare Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.99%

EBIT Growth (5y)

2.66%

EBIT to Interest (avg)

7.73

Debt to EBITDA (avg)

2.11

Net Debt to Equity (avg)

0.70

Sales to Capital Employed (avg)

1.08

Tax Ratio

18.50%

Dividend Payout Ratio

3.08%

Pledged Shares

Institutional Holding

95.22%

ROCE (avg)

18.55%

ROE (avg)

26.44%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.17

EV to EBIT

13.31

EV to EBITDA

11.10

EV to Capital Employed

2.41

EV to Sales

1.87

PEG Ratio

Dividend Yield

0.10%

ROCE (Latest)

18.08%

ROE (Latest)

20.79%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 148 Schemes (42.76%)

Foreign Institutions

Held by 447 Foreign Institutions (19.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 7.41% vs 2.73% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -30.10% vs 51.55% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,131.00",
          "val2": "4,777.00",
          "chgp": "7.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "736.00",
          "val2": "805.00",
          "chgp": "-8.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "134.00",
          "val2": "117.00",
          "chgp": "14.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-62.00",
          "val2": "40.00",
          "chgp": "-255.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "411.00",
          "val2": "588.00",
          "chgp": "-30.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "113.60%",
          "val2": "140.00%",
          "chgp": "-2.64%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 4.84% vs 0.61% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.07% vs 26.70% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "20,625.00",
          "val2": "19,672.00",
          "chgp": "4.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,474.00",
          "val2": "3,536.00",
          "chgp": "-1.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "484.00",
          "val2": "520.00",
          "chgp": "-6.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.00",
          "val2": "-310.00",
          "chgp": "94.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,154.00",
          "val2": "2,050.00",
          "chgp": "5.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "140.40%",
          "val2": "150.30%",
          "chgp": "-0.99%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

5,131.00

4,777.00

7.41%

Operating Profit (PBDIT) excl Other Income

736.00

805.00

-8.57%

Interest

134.00

117.00

14.53%

Exceptional Items

-62.00

40.00

-255.00%

Consolidate Net Profit

411.00

588.00

-30.10%

Operating Profit Margin (Excl OI)

113.60%

140.00%

-2.64%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 7.41% vs 2.73% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -30.10% vs 51.55% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

20,625.00

19,672.00

4.84%

Operating Profit (PBDIT) excl Other Income

3,474.00

3,536.00

-1.75%

Interest

484.00

520.00

-6.92%

Exceptional Items

-16.00

-310.00

94.84%

Consolidate Net Profit

2,154.00

2,050.00

5.07%

Operating Profit Margin (Excl OI)

140.40%

150.30%

-0.99%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 4.84% vs 0.61% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 5.07% vs 26.70% in Dec 2024

All Annual Results

Company CV

About GE Healthcare Technologies, Inc.

GE Healthcare Technologies, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available